Dapagliflozin + Standard of Care BCNU (carmustine) chemotherapy for Pediatric Brain Tumors
Study Summary
This is a pilot study of the feasibility and safety of dapagliflozin (in addition to standard of care treatment) for the treatment of pediatric patients with recurrent brain tumors. The primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious as an adjunct to front-line chemotherapy assessed by decreased tumor markers mediated by its pleiotropic metabolic effects.
Eligible Conditions
- Pediatric Brain Tumors
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 8 Secondary · Reporting Duration: Through completion of treatment for all enrolled patients (estimated to be 39 months)
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Dapagliflozin + Standard of Care BCNU (carmustine) chemotherapy
1 of 1
20 Total Participants · 1 Treatment Group
Primary Treatment: Dapagliflozin + Standard of Care BCNU (carmustine) chemotherapy · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Eligibility Criteria
Age < 65 · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.